A pancreatic cancer drug is showing promising signs of a possible breakthrough after a clinical trial found it nearly doubled ...
Improvement in median overall survival of 2.9 months and decrease in risk for death reported with elraglusib/GnP vs GnP alone.
Trends in incidence and survival in anal adenocarcinoma: A SEER study of racial and age disparities.
Trends and disparities in palliative care utilization among patients with anal cancer: A ten-year retrospective study. This table summarizes the key trends in anal adenocarcinoma incidence and ...
PolyPEPI1018 Cancer Vaccine and TAS-102 for Patients With Advanced, Chemo-Refractory, Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib Nonrandomized Study Using SEER 22 data, we analyzed ...
Elraglusib plus chemotherapy doubled one-year survival in metastatic pancreatic cancer, showing improved outcomes in a phase ...
Investigators compared cancer-specific survival rates after synchronous vs metachronous metastasis in patients with surgically treated renal cell carcinoma (RCC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results